Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per sponsor: Biogen Idec
Woman Max 99 years
Biogen Idec Ltd
Update Il y a 4 ans
A Phase 1/2, Open-Label, Adaptive, Randomized Study of Liposomal Doxorubicin With or Without M200 (Volociximab) for the Treatment of Subjects With Advanced Epithelial Ovarian Cancer or Primary Peritoneal Cancer That Have Relapsed After Prior Therapy With a Platinum/Taxane-Based Chemotherapy
• To evaluate the efficacy of volociximab in combination with liposomal doxorubicin in advanced epithelial ovarian cancer or primary peritoneal cancer. • To evaluate the safety and tolerability of vol...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Biogen Idec Research Limited
Update Il y a 4 ans
221AD301 Phase 3 Study of Aducanumab in Early Alzheimer's Disease Estudio fase 3 de Aducanumab en pacientes con enfermedad de Alzheimer temprana
Placebo-controlled period: To evaluate the efficacy of monthly doses of aducanumab in slowing cognitive and functional impairment as measured by changes in the CDR-SB score as compared with placebo in...
Country
None
organs
None
Specialty
None
unknown
More information
Man Max 99 years
Biogen Idec Research Ltd
Update Il y a 4 ans
A clinical study involving previously untreated patients with haemophilia A to look at how safe an experimental replacement factor VIII protein (known as rFVIIIFc) is to take and how well it works to prevent and stop bleeds
The primary objective of the study is to evaluate the safety of rFVIIIFc in previously untreated subjects with severe hemophilia A.
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Biogen Idec Research Limited
Update Il y a 4 ans
Efficacy and Safety of Daclizumab in Participants with RRMS Switching from Natalizumab
The primary objective of the study is to evaluate the effects of treatment with daclizumab on the proportion of participants relapse-free at 6 months in Relapsing-Remitting Multiple Sclerosis (RRMS) p...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Biogen Idec Ltd
Update Il y a 4 ans
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of AVONEX® in Subjects with Moderate to Severe Ulcerative Colitis
The primary objective of this study is to evaluate the clinical activity of AVONEX in subjects with moderate to severe UC. The primary endpoint is clinical response at Week 8, defined as a decrease fr...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Biogen Idec Research Limited
Update Il y a 4 ans
Study to Evaluate Whether 6-Week Up-Titration in Tecfidera® Dose is Effective in Reducing the Incidence of Gastrointestinal Adverse Events in Patients with Multiple Sclerosis
The primary objective of the study is to assess whether a 6-week titration (compared with a 1-week titration) is effective in reducing the incidence of BG00012-related GI AEs in subjects with MS.
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Biogen Idec Ltd
Update Il y a 4 ans
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Study to Assess The Effects of Intravenous BG9928 on Body Weight in Subjects with Acute Decompensated Heart Failure and Renal Insufficiency
To assess the effect of BG9928, when added to standard therapy, on the change in body weight at 24 hours following the first dose in subjects hospitalized with ADHF and renal insufficiency.
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man
Between 18 years
and 99 years
Biogen Idec
Update Il y a 4 ans
Biogen 152CL201 : Essai de phase 2, 3 randomisé évaluant l’efficacité et la tolérance d’un traitement par fludarabine, cyclophosphamide et rituximab associé ou non à lumiliximab chez des paitients ayant une leucémie lymphoïde chronique. [Informations issues du site clinicaltrials.gov et traduites par l'INCa] [essai clos aux inclusions]
L’objectif de l’essai est d’évaluer l’efficacité et la tolérance d’un traitement associant fludarabine, cyclophosphamide et rituximab au lumiliximab chez des patients ayant une leucémie lymphoïde chro...
Country
France
organs
Leucémies chroniques
Specialty
Chimiothérapie
,
Thérapies Ciblées
Essai clos aux inclusions
More information
Woman and Man Max 99 years
Biogen Idec Ltd
Update Il y a 4 ans
A Phase III, Randomized, Double-Blind Study of Galiximab in Combination with Rituximab Compared with Rituximab in Combination with Placebo for the Treatment of Subjects with Relapsed or Refractory, Follicular Non Hodgkin’s Lymphoma
To compare the clinical benefit of galiximab in combination with rituximab with that of rituximab monotherapy for the treatment of subjects with relapsed or refractory, follicular NHL.
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Biogen Idec Research Limited
Update Il y a 4 ans
A Clinical Study of the Safety and Efficacy of Natalizumab in Acute Ischemic Stroke Estudio Clinico de la Seguridad y eficacia de Natalizumab en accidente cerebrovascular isquémico agudo
The primary objective of the study is to determine whether one 300 mg dose of intravenous (IV) natalizumab reduces change in infarct volume from Baseline to Day 5 on magnetic resonance imaging (MRI) i...
Country
None
organs
None
Specialty
None
Closed trial
More information
Previous
3
4
5
6
7
8
9
Next